The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
Open accessAbstract
To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
A safe packaging line for gene transfer: separating viral genes on two different plasmids
Markowitz, D., Goff, S., & Bank, A. (1988) · Journal of Virology · doi:10.1128/jvi.62.4.1120-1124.1988 · Cited by 1,061
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Two types of mouse helper T-cell clone
Mosmann, T. R., & Coffman, R. L. (1987) · Immunology Today · doi:10.1016/0167-5699(87)90171-x · Cited by 801
Murine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 778
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.
Ej, F. (1953) · PubMed · Cited by 690
Construction and use of a safe and efficient amphotropic packaging cell line
MARKOWITZ, D., GOFF, S., & BANK, A. (1988) · Virology · doi:10.1016/s0042-6822(88)90101-8 · Cited by 670
The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene
McKnight, S. L. (1980) · Nucleic Acids Research · doi:10.1093/nar/8.24.5949 · Cited by 528
Cited by
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Human gene therapy comes of age
Miller, A. D. (1992) · Nature · doi:10.1038/357455a0 · Cited by 908
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Paracrine Cytokine Adjuvants in Cancer Immunotherapy
Pardoll, D. M. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.399 · Cited by 369
Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358
Interferons and Other Cytokines
Hendrzak, J. A., & Brunda, M. J. (1997) · Cancer Therapeutics · doi:10.1007/978-1-59259-717-8_13 · Cited by 356
Duration of TCR Stimulation Determines Costimulatory Requirement of T Cells
Kündig, T. M., Shahinian, A., Kawai, K., Mittrücker, H.-W., Sebzda, E., Bachmann, M. F., Mak, T. W., & Ohashi, P. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80308-8 · Cited by 355
Udono, H., Levey, D. L., & Srivastava, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3077 · Cited by 347
Immunotherapy of malignancy by in vivo gene transfer into tumors.
Plautz, G. E., Yang, Z. Y., Wu, B. Y., Gao, X., Huang, L., & Nabel, G. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4645 · Cited by 317
Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., & Parmiani, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.889 · Cited by 313
Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs
Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., et al. (1995) · Science · doi:10.1126/science.7761853 · Cited by 301
Immunotherapy of cancer with dendritic-cell-based vaccines
Gilboa, E., Nair, S. K., & Lyerly, H. K. (1998) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050465 · Cited by 287
Self-citationTumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60294-8 · Cited by 275
A brief history of gene therapy
Friedmann, T. (1992) · Nature Genetics · doi:10.1038/ng1092-93 · Cited by 273
Young, J. W., & Inaba, K. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.7 · Cited by 269
RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE
FIGLIN, R. A. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61897-4 · Cited by 266
Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells
Tepper, R. I., & Mulé, J. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-153 · Cited by 254
Qin, H., Valentino, J., Manna, S., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A., O'Malley, B. W., & Chatterjee, S. K. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0493 · Cited by 44
Metadata
- Authors
- Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., & Gilboa, E.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1990-10-01
- Volume
- 172
- Issue
- 4
- Pages
- 1217-1224
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2002323372
- Cited by
- 620
- References
- 23
- FWCI
- 17.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.